Expression of DNA-damage response and repair genes after exposure to DNA-damaging agents in isogenic head and neck cells with altered radiosensitivity.
DNA-damaging agents
gene expression profiles
head and neck cancer
irradiation
radioresistance
squamous cell carcinoma
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
07 04 2022
07 04 2022
Historique:
received:
25
02
2022
accepted:
16
03
2022
pubmed:
8
4
2022
medline:
20
5
2022
entrez:
7
4
2022
Statut:
epublish
Résumé
Increased radioresistance due to previous irradiation or radiosensitivity due to human papilloma virus (HPV) infection can be observed in head and neck squamous cell carcinoma (HNSCC). The DNA-damage response of cells after exposure to DNA-damaging agents plays a crucial role in determining the fate of exposed cells. Tightly regulated and interconnected signaling networks are activated to detect, signal the presence of and repair the DNA damage. Novel therapies targeting the DNA-damage response are emerging; however, an improved understanding of the complex signaling networks involved in tumor radioresistance and radiosensitivity is needed. In this study, we exposed isogenic human HNSCC cell lines with altered radiosensitivity to DNA-damaging agents: radiation, cisplatin and bleomycin. We investigated transcriptional alterations in the DNA-damage response by using a pathway-focused panel and reverse-transcription quantitative PCR. In general, the isogenic cell lines with altered radiosensitivity significantly differed from one another in the expression of genes involved in the DNA-damage response. The radiosensitive (HPV-positive) cells showed overall decreases in the expression levels of the studied genes. In parental cells, upregulation of DNA-damage signaling and repair genes was observed following exposure to DNA-damaging agents, especially radiation. In contrast, radioresistant cells exhibited a distinct pattern of gene downregulation after exposure to cisplatin, whereas the levels in parental cells were unchanged. Exposure of radioresistant cells to bleomycin did not significantly affect the expression of DNA-damage signaling and repair genes. Our analysis identified several possible targets: NBN, XRCC3, ATR, GADD45A and XPA. These putative targets should be studied and potentially exploited for sensibilization to ionizing radiation and/or cisplatin in HNSCC. The use of predesigned panels of DNA-damage signaling and repair genes proved to offer a convenient and quick approach to identify possible therapeutic targets.
Sections du résumé
BACKGROUND
Increased radioresistance due to previous irradiation or radiosensitivity due to human papilloma virus (HPV) infection can be observed in head and neck squamous cell carcinoma (HNSCC). The DNA-damage response of cells after exposure to DNA-damaging agents plays a crucial role in determining the fate of exposed cells. Tightly regulated and interconnected signaling networks are activated to detect, signal the presence of and repair the DNA damage. Novel therapies targeting the DNA-damage response are emerging; however, an improved understanding of the complex signaling networks involved in tumor radioresistance and radiosensitivity is needed.
MATERIALS AND METHODS
In this study, we exposed isogenic human HNSCC cell lines with altered radiosensitivity to DNA-damaging agents: radiation, cisplatin and bleomycin. We investigated transcriptional alterations in the DNA-damage response by using a pathway-focused panel and reverse-transcription quantitative PCR.
RESULTS
In general, the isogenic cell lines with altered radiosensitivity significantly differed from one another in the expression of genes involved in the DNA-damage response. The radiosensitive (HPV-positive) cells showed overall decreases in the expression levels of the studied genes. In parental cells, upregulation of DNA-damage signaling and repair genes was observed following exposure to DNA-damaging agents, especially radiation. In contrast, radioresistant cells exhibited a distinct pattern of gene downregulation after exposure to cisplatin, whereas the levels in parental cells were unchanged. Exposure of radioresistant cells to bleomycin did not significantly affect the expression of DNA-damage signaling and repair genes.
CONCLUSIONS
Our analysis identified several possible targets: NBN, XRCC3, ATR, GADD45A and XPA. These putative targets should be studied and potentially exploited for sensibilization to ionizing radiation and/or cisplatin in HNSCC. The use of predesigned panels of DNA-damage signaling and repair genes proved to offer a convenient and quick approach to identify possible therapeutic targets.
Identifiants
pubmed: 35390246
pii: raon-2022-0014
doi: 10.2478/raon-2022-0014
pmc: PMC9122295
doi:
Substances chimiques
Bleomycin
11056-06-7
DNA
9007-49-2
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-184Informations de copyright
© 2022 Vesna Todorovic, Blaz Groselj, Maja Cemazar, Ajda Prevc, Martina Niksic Zakelj, Primoz Strojan, Gregor Sersa, published by Sciendo.
Références
Maréchal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 2013; 5: a012716. doi: 10.1101/cshperspect.a012716
doi: 10.1101/cshperspect.a012716
Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumor Biol 2010; 31: 363-72. doi: 10.1007/s13277-010-0042-8
doi: 10.1007/s13277-010-0042-8
Lomax ME, Folkes LK, O’Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol 2013; 25: 578-85. doi: 10.1016/j.clon.2013.06.007
doi: 10.1016/j.clon.2013.06.007
Hu J, Lieb JD, Sancar A, Adar S. Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proc Natl Acad Sci 2016; 13: 11507-12. doi: 10.1073/pnas.1614430113
doi: 10.1073/pnas.1614430113
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-83. doi: 10.1038/onc.2011.384
doi: 10.1038/onc.2011.384
Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 2019; 53: 148-58. doi: 10.2478/raon-2019-0018
doi: 10.2478/raon-2019-0018
Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005; 5: 102-12. doi: 10.1038/nrc1547
doi: 10.1038/nrc1547
Allawzi A, Elajaili H, Redente EF, Nozik-Grayck E. Oxidative toxicology of bleomycin: role of the extracellular redox environment. Physiol Behav 2016; 176: 139-48. doi: 10.1016/j.cotox.2018.08.001
doi: 10.1016/j.cotox.2018.08.001
Strojan P, Corry J, Eisbruch A, Vermorken JB, Mendenhall WM, Lee AWM, et al. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck 2015; 37: 134-50. doi: 10.1002/hed.23542
doi: 10.1002/hed.23542
Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100: 33-40. doi: 10.1016/j.radonc.2011.05.036
doi: 10.1016/j.radonc.2011.05.036
Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol 2014; 50: 56574. doi: 10.1016/j.oraloncology.2013.09.008
doi: 10.1016/j.oraloncology.2013.09.008
Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives. Cancer Treat Rev 2015; 41: 844-52. doi: 10.1016/j.ctrv.2015.10.001
doi: 10.1016/j.ctrv.2015.10.001
Wierzbicka M, Szyfter K, Milecki P, Składowski K, Ramlau R. The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies. Contemp Oncol 2015; 19: 313-22. doi: 10.5114/wo.2015.54389
doi: 10.5114/wo.2015.54389
Prevc A, Kranjc S, Cemazar M, Todorovic V, Zegura B, Novak M, et al. Dose-modifying factor of radiation therapy with concurrent cisplatin treatment in HPV-positive squamous cell carcinoma: a preclinical study. Radiat Res 2018; 189: 644-51. doi: 10.1667/RR14984.1
doi: 10.1667/RR14984.1
Kimple RJ, Harari PM. Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol 2014; 50: 560-4. doi: 10.1016/j.oraloncology.2013.09.015
doi: 10.1016/j.oraloncology.2013.09.015
Adema AD, Cloos J, Verheijen RHM, Braakhuis BJM, Bryant PE. Comparison of bleomycin and radiation in the G2 assay of chromatid breaks. Int J Radiat Biol 2003; 79: 655-61. doi: 10.1080/09553000310001596968
doi: 10.1080/09553000310001596968
O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015; 60: 547-60. doi: 10.1016/j.molcel.2015.10.040
doi: 10.1016/j.molcel.2015.10.040
Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov 2017; 7: 20-37. doi: 10.1158/2159-8290.CD-16-0860
doi: 10.1158/2159-8290.CD-16-0860
Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013; 73: 4791-800. doi: 10.1158/0008-5472.CAN-13-0587
doi: 10.1158/0008-5472.CAN-13-0587
Park JW, Nickel KP, Torres AD, Lee D, Lambert PF, Kimple RJ. Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. Radiother Oncol 2014; 113: 337-44. doi: 10.1016/j.radonc.2014.08.026
doi: 10.1016/j.radonc.2014.08.026
Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol - Head Neck Surg 2009; 135: 1137-46. doi: 10.1001/archoto.2009.159
doi: 10.1001/archoto.2009.159
McDermott N, Meunier A, Lynch TH, Hollywood D, Marignol L. Isogenic radiation resistant cell lines: development and validation strategies. Int J Radiat Biol 2014; 90: 115-26. doi: 10.3109/09553002.2014.873557
doi: 10.3109/09553002.2014.873557
Todorovic V, Prevc A, Zakelj MN, Savarin M, Brozic A, Groselj B, et al. Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines. Radiat Oncol 2019; 14: 1-20. doi: 10.1186/ s13014-019-1418-6
doi: 10.1186/s13014-019-1418-6
Harris M, Wang XG, Jiang Z, Goldberg GL, Casadevall A, Dadachova E. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol 2011; 3: 9. doi: 10.1186/1758-3284-3-9
doi: 10.1186/1758-3284-3-9
Reiss M, Brash D, Muñoz-Antonia T, Simon J, Ziegler A, Vellucci V, et al. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 1992; 4: 349-57. PMID:1486218
Prevc A, Niksic Zakelj M, Kranjc S, Cemazar M, Scancar J, Kosjek T, et al. Electrochemotherapy with cisplatin or bleomycin in head and neck squamous cell carcinoma: improved effectiveness of cisplatin in HPV-positive tumors. Bioelectrochemistry 2018; 123: 248-54. doi: 10.1016/j.bioelechem.2018.06.004
doi: 10.1016/j.bioelechem.2018.06.004
Zakelj MN, Prevc A, Kranjc S, Cemazar M, Todorovic V, Savarin M, et al. Electrochemotherapy of radioresistant head and neck squamous cell carcinoma cells and tumor xenografts. Oncol Rep 2019; 41: 1658-68. doi: 10.3892/or.2019.6960
doi: 10.3892/or.2019.6960
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034. doi: 10.1186/gb-2002-3-7-research0034
doi: 10.1186/gb-2002-3-7-research0034
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001; 25: 402-8. doi: 10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. doi: 10.1016/j.cell.2011.02.013
doi: 10.1016/j.cell.2011.02.013
Blasiak J. DNA-damaging anticancer drugs – a perspective for DNA repair-oriented therapy. Curr Med Chem 2017; 24: 1488-503. doi: 10.2174/0929867324666170124145557
doi: 10.2174/0929867324666170124145557
Arenz A, Ziemann F, Mayer C, Wittig A, Dreffke K, Preising S, et al. Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther Onkol 2014; 190: 839-46. doi: 10.1007/s00066-014-0605-5
doi: 10.1007/s00066-014-0605-5
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9. doi: 10.1093/jnci/djn011
doi: 10.1093/jnci/djn011
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35. doi: 10.1056/NEJMoa0912217
doi: 10.1056/NEJMoa0912217
Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch C-JJ, Petersen C, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol 2013; 107: 242-6. doi: 10.1016/j.radonc.2013.03.013
doi: 10.1016/j.radonc.2013.03.013
Masterson L, Moualed D, Liu ZW, Howard JEF, Dwivedi RC, Tysome JR, et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 2014; 50: 2636-48. doi: 10.1016/j.ejca.2014.07.001
doi: 10.1016/j.ejca.2014.07.001
Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell 2017; 66: 801-17. doi: 10.1016/j.molcel.2017.05.015
doi: 10.1016/j.molcel.2017.05.015
McGowan CH, Russell P. The DNA damage response: sensing and signaling. Curr Opin Cell Biol 2004; 16: 629-33. doi: 10.1016/j.ceb.2004.09.005
doi: 10.1016/j.ceb.2004.09.005
Buisson R, Niraj J, Rodrigue A, Ho CK, Kreuzer J, Foo TK, et al. Coupling of homologous recombination and the checkpoint by ATR. Mol Cell 2017; 65: 336-46. doi: 10.1016/j.molcel.2016.12.007
doi: 10.1016/j.molcel.2016.12.007
Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, et al. ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncol 2019; 95: 35-42. doi: 10.1016/j.oraloncol-ogy.2019.05.028
doi: 10.1016/j.oraloncol-ogy.2019.05.028
Sankunny M, Parikh RA, Lewis DW, Gooding WE, Saunders WS, Gollin SM. Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss. Genes Chromosomes Cancer 2014; 53: 129-43. doi: 10.1002/gcc.22125
doi: 10.1002/gcc.22125
Wang H, Wang H, Powell SN, Iliakis G, Wang Y. ATR Affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res 2004; 64: 7139-43. doi: 10.1158/0008-5472.CAN-04-1289
doi: 10.1158/0008-5472.CAN-04-1289
Bian L, Meng Y, Zhang M, Li D. MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Molecular Cancer 2019; 18: 169. doi: 10.1186/s12943-019-1100-5
doi: 10.1186/s12943-019-1100-5
Prati B, da Silva Abjaude W, Termini L, Morale M, Herbster S, Longatto-Filho A, et al. Three Prime Repair Exonuclease 1 (TREX1) expression correlates with cervical cancer cells growth in vitro and disease progression in vivo. Sci Rep 2019; 9: 351. doi: 10.1038/s41598-018-37064-x
doi: 10.1038/s41598-018-37064-x
Girard PM, Foray N, Stumm M, Waugh A, Riballo E, Maser RS, et al. Radiosensitivity in nijmegen breakage syndrome cells is attributable to a repair defect and not cell cycle checkpoint defects. Cancer Res 2000; 60: 4881-8. PMID: 10987302
Cheng J, Liu W, Zeng X, Zhang B, Guo Y, Qiu M, et al. XRCC3 is a promising target to improve the radiotherapy effect of esophageal squamous cell carcinoma. Cancer Sci 2015; 106: 1678-86. doi: 10.1111/cas.12820
doi: 10.1111/cas.12820
Westermark UK, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan ME. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol 2003; 23: 7926-36. doi: 10.1128/mcb.23.21.7926-7936.2003
doi: 10.1128/mcb.23.21.7926-7936.2003
Isono M, Niimi A, Oike T, Hagiwara Y, Sato H, Sekine R, et al. BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation. Cell Rep 2017; 18: 520-32. doi: 10.1016/j.cel-rep.2016.12.042
doi: 10.1016/j.cel-rep.2016.12.042
Kakarougkas A, Jeggo PA. DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol 2014; 87: 20130685. doi: 10.1259/bjr.20130685
doi: 10.1259/bjr.20130685
Litwin I, Pilarczyk E, Wysocki R. The emerging role of cohesin in the DNA damage response. Genes 2018; 9: 581. doi: 10.3390/genes9120581
doi: 10.3390/genes9120581
Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids 2010; 2010: 1-16. doi: 10.4061/2010/201367
doi: 10.4061/2010/201367
Marullo R, Werner E, Zhang H, Chen GZ, Shin DM, Doetsch PW. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis 2015; 36: 1397-406. doi: 10.1093/carcin/bgv126
doi: 10.1093/carcin/bgv126
Harvie RM, Davey MW, Davey RA. Increased MRP expression is associated with resistance to radiation, anthracyclines and etoposide in cells treated with fractionated gamma-radiation. Int J Cancer 1997; 73: 164-7. doi: 10.1002/(SICI)1097-0215(19970926)73:1<164::AID-IJC25>3.0.CO;2-F
doi: 10.1002/(SICI)1097-0215(19970926)73:1<164::AID-IJC25>3.0.CO;2-F
McDermott N, Meunier A, Mooney B, Nortey G, Hernandez C, Hurley S, et al. Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells. Sci Rep 2016; 6: 34796. doi: 10.1038/srep34796
doi: 10.1038/srep34796
Skvortsov S, Dudás J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, et al. Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC). Br J Cancer 2014; 110: 2677-87. doi: 10.1038/bjc.2014.221
doi: 10.1038/bjc.2014.221
Wei QC, Shen L, Zheng S, Zhu YL. Isolation and characterization of radiation-resistant lung cancer D6-R cell line. Biomed Environ Sci 2008; 21: 339-44. doi: 10.1016/S0895-3988(08)60052-5
doi: 10.1016/S0895-3988(08)60052-5
Xie L, Song X, Yu J, Wei L, Song B, Wang X, et al. Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. J Exp Clin Cancer Res 2009; 28: 68. doi: 10.1186/1756-9966-28-68
doi: 10.1186/1756-9966-28-68
Kleinsimon S, Longmuss E, Rolff J, Jäger S, Eggert A, Delebinski C, et al. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. Sci Rep 2018; 8: 1-14. doi: 10.1038/s41598-018-24075-x
doi: 10.1038/s41598-018-24075-x
Rosemary Siafakas A, Richardson DR. Growth arrest and DNA damage-45 alpha (GADD45α). Int J Biochem Cell Biol 2009; 41: 986-9. doi: 10.1016/j.biocel.2008.06.018
doi: 10.1016/j.biocel.2008.06.018
Wang BX, Yin BL, He B, Chen C, Zhao M, Zhang WX, et al. Overexpression of DNA damage-induced 45 a gene contributes to esophageal squamous cell cancer by promoter hypomethylation. J Exp Clin Cancer Res 2012; 31: 11. doi: 10.1186/1756-9966-31-11
doi: 10.1186/1756-9966-31-11
Barreto G, Schäfer A, Swaminathan SK, Döderlein G, Maltry N, Stach D, et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007; 445: 671-5. doi: 10.1038/nature05515
doi: 10.1038/nature05515
Tamura R, Vasconcellos JF De, Libermann T, Israel B, Medical D, Fisher PB, et al. GADD45 proteins: central players in tumorigenesis. Curr Mol Med 2012; 12: 634-51. doi: 10.2174/156652412800619978
doi: 10.2174/156652412800619978
Liu J, Jiang G, Mao P, Zhang J, Zhang L, Liu L, et al. Down-regulation of GADD45A enhances chemosensitivity in melanoma. Sci Rep 2018; 8: 4111. doi: 10.1038/s41598-018-22484-6
doi: 10.1038/s41598-018-22484-6
Zhang X, Xun Qu, Cheng-qin Wang, Cheng-jun Zhou, Gui-xiang Liu, Feng-cai Wei, et al. Over-expression of Gadd45a enhances radiotherapy efficacy in human Tca8113 cell line. Acta Pharmacol Sin 2011; 32: 253-8. doi: 10.1038/aps.2010.208
doi: 10.1038/aps.2010.208
Hollander MC, Sheikh MS, Bulavin D V, Lundgren K, Augeri-henmueller L, Shehee R, et al. Genomic instability in Gadd45a-deficient mice. Nat Genet 1999; 23: 176-84. doi: 10.1038/13802
doi: 10.1038/13802
Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E. Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response. Mutat Res 2010; 704: 12-20. doi: 10.1016/j.mrrev.2010.01.009
doi: 10.1016/j.mrrev.2010.01.009
Hutchinson MND Mierzwa M, Silva NJ. Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer. Oncogene 2020; 39: 3638-49. doi: 10.1038/s41388-020-1250-3
doi: 10.1038/s41388-020-1250-3
Sun C, Wang Z, Song W, Chen B, Zhang J, Dai X, et al. Alteration of DNA damage signaling pathway profile in radiation-treated glioblastoma stem-like cells. Oncol Lett 2015; 10:1769-74. doi: 10.3892/ol.2015.3411
doi: 10.3892/ol.2015.3411
Zhao J, Jain A, Iyer RR, Modrich PL, Vasquez KM. Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks. Nucleic Acids Res 2009; 37: 4420-9. doi: 10.1093/nar/gkp399
doi: 10.1093/nar/gkp399
Fu X, Hu J, Han HY, Hua YJ, Zhou L, Shuai W Di, et al. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy. Oncotarget 2015; 6: 28478-90. doi: 10.18632/oncotarget.4424
doi: 10.18632/oncotarget.4424
Liu Y, Bernauer AM, Yingling CM, Belinsky SA. HIF1a regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 2012; 33: 1-6. doi: 10.1093/carcin/bgs142
doi: 10.1093/carcin/bgs142
Leemans C, Braakhuis B, Brakenhoff R. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22. doi: 10.1038/nrc2982
doi: 10.1038/nrc2982
Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol 2000; 20: 2803-8. doi: 10.1128/MCB.20.8.2803-2808.2000
doi: 10.1128/MCB.20.8.2803-2808.2000
Stiff T, Reis C, Alderton GK, Woodbine L, O’Driscoll M, Jeggo PA. Nbs1 is required for ATR-dependent phosphorylation events. EMBO J 2005; 24: 199-208. doi: 10.1038/sj.emboj.7600504
doi: 10.1038/sj.emboj.7600504